| P50 | author | Wolfdieter Springer | Q56875665 |
| P2093 | author name string | X Wang | |
| | S Akhtar | |
| | A Manna | |
| | A Chanan-Khan | |
| | Y Bashir | |
| | R Hudec | |
| | S Ailawadhi | |
| | A Paulus | |
| | K Chitta | |
| | T R Caulfield | |
| | Y Asmann | |
| | H Yousaf | |
| | M Kuranz-Blake | |
| | S M Paulus | |
| P2860 | cites work | The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 |
| | Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. | Q40392114 |
| | Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab | Q40487647 |
| | Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. | Q40831748 |
| | Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib | Q41601558 |
| | Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells | Q42355443 |
| | Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells. | Q50950235 |
| | The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia. | Q54346075 |
| | Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. | Q55070853 |
| | CD19 is essential for B cell activation by promoting B cell receptor–antigen microcluster formation in response to membrane-bound ligand | Q63408317 |
| | Bcl-2 antisense therapy in multiple myeloma | Q81272841 |
| | Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner | Q82973646 |
| | MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia | Q85732520 |
| | CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells | Q85911270 |
| | The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells | Q86516013 |
| | Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia | Q87325788 |
| | Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells | Q27314737 |
| | ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 |
| | Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib | Q27853011 |
| | Ibrutinib in previously treated Waldenström's macroglobulinemia. | Q27853148 |
| | The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis | Q28304614 |
| | Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 |
| | Direct multiplexed measurement of gene expression with color-coded probe pairs | Q29614417 |
| | Targeting multidrug resistance in cancer | Q29616803 |
| | Postibrutinib outcomes in patients with mantle cell lymphoma | Q30277756 |
| | Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia | Q30848149 |
| | Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia | Q33374227 |
| | Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma | Q34135450 |
| | Ibrutinib treatment of CLL: the cancer fights back | Q34352273 |
| | Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 |
| | Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers | Q34518245 |
| | Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia | Q35116840 |
| | Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial | Q35168763 |
| | Waldenstrom macroglobulinemia: prognosis and management | Q35244911 |
| | Immunophenotyping of Waldenströms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications | Q35597598 |
| | Bcl-2 antisense therapy in B-cell malignant proliferative disorders | Q35826461 |
| | Ibrutinib resistance in chronic lymphocytic leukemia | Q35881570 |
| | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 |
| | Bcl-2 antisense therapy in hematologic malignancies | Q35997237 |
| | Bcl-2 antisense therapy in B-cell malignancies | Q36077463 |
| | Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) | Q36349985 |
| | Targeting the Bcl-2. | Q37591811 |
| | Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma. | Q37621361 |
| | Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia | Q37869144 |
| | "Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia''. | Q38140625 |
| | Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma | Q38413580 |
| | Preclinical models of Waldenström's macroglobulinemia and drug resistance | Q38732286 |
| | Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. | Q38959765 |
| | Novel therapeutic targets in Waldenstrom macroglobulinemia | Q39003121 |
| | AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia | Q39062888 |
| | Coordination of mitochondrial bioenergetics with G1 phase cell cycle progression | Q39967749 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P921 | main subject | ibrutinib | Q5984881 |
| | MK-2206 | Q25100065 |
| P304 | page(s) | e565 | |
| P577 | publication date | 2017-05-26 | |
| P1433 | published in | Blood Cancer Journal | Q2464036 |
| P1476 | title | Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment | |
| P478 | volume | 7 | |